Palbociclib With Everolimus + Exemestane In BC
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast|Hormone Receptor (HR)-Positive Breast Cancer
Interventions: DRUG: Palbociclib|DRUG: Everolimus|DRUG: Exemestane
Sponsor: Dana-Farber Cancer Institute
Collaborators: Pfizer